BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21434519)

  • 1. Image cytometric validation of breast carcinoma markers (ER, HER2 and MIB-1) using tissue microarrays: rabbit monoclonal vs. FDA-approved antibodies.
    Nassar A; Norton CM; Lawson D; Cohen C
    Anal Quant Cytol Histol; 2010 Aug; 32(4):192-200. PubMed ID: 21434519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of new monoclonal antibodies in detection of estrogen receptor, progesterone receptor, and Her2 protein expression in breast carcinoma cell block sections using conventional microscopy and quantitative image analysis.
    Hanley KZ; Siddiqui MT; Lawson D; Cohen C; Nassar A
    Diagn Cytopathol; 2009 Apr; 37(4):251-7. PubMed ID: 19217031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estimation of hormone receptor status and HER2 in cytologic cell blocks from breast cancer using the novel rabbit monoclonal antibodies (SP1, SP2, and SP3).
    Nassar A; Cohen C; Siddiqui M
    Diagn Cytopathol; 2009 Dec; 37(12):865-70. PubMed ID: 19530101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of six different antibodies against Her2 including the novel rabbit monoclonal antibody (SP3) and chromogenic in situ hybridisation in breast carcinomas.
    Nunes CB; Rocha RM; Reis-Filho JS; Lambros MB; Rocha GF; Sanches FS; Oliveira FN; Gobbi H
    J Clin Pathol; 2008 Aug; 61(8):934-8. PubMed ID: 18474540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Image cytometric HER2 in gastric carcinoma: is a new algorithm needed?
    Ormenisan C; Wang J; Lawson D; Cohen C
    Appl Immunohistochem Mol Morphol; 2013 Oct; 21(5):414-9. PubMed ID: 23197004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. False positivity in HER2 testing of breast cancer: novel paths for approaching an old dilemma.
    Nunes CB; Rocha RM; Buzelin MA; Balabram D; de Souza Foureaux F; Porto SS; Gobbi H
    J Clin Pathol; 2013 Nov; 66(11):946-50. PubMed ID: 23867547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of immunohistochemical analysis with estrogen receptor SP1 and 1D5 monoclonal antibodies in breast cancer.
    Madeira KP; Daltoé RD; Sirtoli GM; Rezende LC; Carvalho AA; Guimarães Idos S; Silva IV; Rangel LB
    Pathol Res Pract; 2012 Nov; 208(11):657-61. PubMed ID: 23017667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas.
    Ricardo SA; Milanezi F; Carvalho ST; Leitão DR; Schmitt FC
    J Clin Pathol; 2007 Sep; 60(9):1001-5. PubMed ID: 17158643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study on breast carcinoma Her2/neu and hormonal receptors status assessed by automated images analysis systems: ACIS III (Dako) and ScanScope (Aperio).
    Słodkowska J; Filas V; Buszkiewicz E; Trzeciak P; Wojciechowski M; Koktysz R; Staniszewski W; Breborowicz J; Rojo MG
    Folia Histochem Cytobiol; 2010 Jan; 48(1):19-25. PubMed ID: 20529811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: a tissue microarray-based study.
    Nassar A; Radhakrishnan A; Cabrero IA; Cotsonis GA; Cohen C
    Appl Immunohistochem Mol Morphol; 2010 Oct; 18(5):433-41. PubMed ID: 20485156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.
    Cheang MC; Treaba DO; Speers CH; Olivotto IA; Bajdik CD; Chia SK; Goldstein LC; Gelmon KA; Huntsman D; Gilks CB; Nielsen TO; Gown AM
    J Clin Oncol; 2006 Dec; 24(36):5637-44. PubMed ID: 17116944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas.
    Gouvêa AP; Milanezi F; Olson SJ; Leitao D; Schmitt FC; Gobbi H
    Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):103-8. PubMed ID: 16540740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rabbit antibodies for hormone receptors and HER2 evaluation in breast cancer.
    Rocha RM; Nunes CB; Sanches FS; Rocha GF; Oliveira FN; Reis-Filho JS; Lambros MB; Gobbi H
    Rev Assoc Med Bras (1992); 2009; 55(2):163-8. PubMed ID: 19488652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proficiency testing of immunohistochemical biomarker assays in breast cancer.
    Wasielewski Rv; Hasselmann S; Rüschoff J; Fisseler-Eckhoff A; Kreipe H
    Virchows Arch; 2008 Dec; 453(6):537-43. PubMed ID: 18958494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High concordance of SP3 rabbit monoclonal antibody with FISH to evaluate HER2 in breast carcinoma.
    Wludarski SC; Bacchi CE
    Appl Immunohistochem Mol Morphol; 2008 Oct; 16(5):466-70. PubMed ID: 18633320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rabbit monoclonal antibodies show higher sensitivity than mouse monoclonals for estrogen and progesterone receptor evaluation in breast cancer by immunohistochemistry.
    Rocha R; Nunes C; Rocha G; Oliveira F; Sanches F; Gobbi H
    Pathol Res Pract; 2008; 204(9):655-62. PubMed ID: 18565685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer.
    Birner P; Oberhuber G; Stani J; Reithofer C; Samonigg H; Hausmaninger H; Kubista E; Kwasny W; Kandioler-Eckersberger D; Gnant M; Jakesz R;
    Clin Cancer Res; 2001 Jun; 7(6):1669-75. PubMed ID: 11410505
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The reliability of rabbit monoclonal antibodies in the immunohistochemical assessment of estrogen receptors, progesterone receptors, and HER2 in human breast carcinomas.
    Rhodes A; Sarson J; Assam EE; Dean SJ; Cribb EC; Parker A
    Am J Clin Pathol; 2010 Oct; 134(4):621-32. PubMed ID: 20855644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Determination of receptor and HER2 status of breast cancer using tissue matrix technology. Validation of the method].
    Kudaibergenova AG; Turkevich EA; Artemieva AS
    Vopr Onkol; 2016; 62(2):314-9. PubMed ID: 30461252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2/neu detection by immunohistochemistry: optimization of in-house protocols.
    Lourenço HM; Pereira TP; Fonseca RR; Cardoso PM
    Appl Immunohistochem Mol Morphol; 2009 Mar; 17(2):151-7. PubMed ID: 18971784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.